{
    "title": "110_hr1902",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Protecting Consumer Access to \nGeneric Drugs Act of 2007''.\n\nSEC. 2. UNFAIR AND DECEPTIVE ACTS AND PRACTICES RELATED TO NEW DRUG \n              APPLICATIONS.\n\n    (a) Conduct Prohibited.--It shall be unlawful for any person to \ndirectly or indirectly be a party to any agreement resolving or \nsettling a patent infringement claim in which--\n            (1) an ANDA filer receives anything of value; and\n            (2) the ANDA filer agrees not to research, develop, \n        manufacture, market, or sell, for any period of time, the drug \n        that is to be manufactured under the ANDA involved and is the \n        subject of the patent infringement claim.\n    (b) Exceptions.--Notwithstanding subsection (a)(1), subsection (a) \ndoes not prohibit a resolution or settlement of a patent infringement \nclaim in which the value received by the ANDA filer includes no more \nthan--\n            (1) the right to market the drug that is to be manufactured \n        under the ANDA involved and is the subject of the patent \n        infringement claim, before the expiration of--\n                    (A) the patent that is the basis for the patent \n                infringement claim; or\n                    (B) any other statutory exclusivity that would \n                prevent the marketing of such drug; and\n            (2) the waiver of a patent infringement claim for damages \n        based on prior marketing of such drug.\n    (c) Enforcement.--A violation of subsection (a) shall be treated as \nan unfair and deceptive act or practice and an unfair method of \ncompetition in or affecting interstate commerce prohibited under \nsection 5 of the Federal Trade Commission Act (15 U.S.C. 45). The \nFederal Trade Commission shall enforce this Act in the same manner, by \nthe same means, and with the same jurisdiction as though all applicable \nterms and provisions of the Federal Trade Commission Act were \nincorporated into and made a part of this Act.\n    (d) Definitions.--In this section:\n            (1) Agreement.--The term ``agreement'' means anything that \n        would constitute an agreement for purposes of section 5 of the \n        Federal Trade Commission Act (15 U.S.C. 45).\n            (2) Agreement resolving or settling.--The term ``agreement \n        resolving or settling'', in reference to a patent infringement \n        claim, includes any agreement that is contingent upon, provides \n        a contingent condition for, or is otherwise related to the \n        resolution or settlement of the claim.\n            (3) ANDA.--The term ``ANDA'' means an abbreviated new drug \n        application for the approval of a new drug under section 505(j) \n        of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)).\n            (4) ANDA filer.--The term ``ANDA filer'' means a party that \n        has filed an ANDA with the Food and Drug Administration.\n            (5) Patent infringement.--The term ``patent infringement'' \n        means infringement of any patent or of any filed patent \n        application, extension, reissuance, renewal, division, \n        continuation, continuation in part, reexamination, patent term \n        restoration, patent of addition, or extension thereof.\n            (6) Patent infringement claim.--The term ``patent \n        infringement claim'' means any allegation made to an ANDA \n        filer, whether or not included in a complaint filed with a \n        court of law, that its ANDA or drug to be manufactured under \n        such ANDA may infringe any patent.\n\nSEC. 3. FTC RULEMAKING.\n\n    The Federal Trade Commission may, by rule promulgated under section \n553 of title 5, United States Code, exempt certain agreements described \nin section 2 if the Commission finds such agreements to be in \nfurtherance of market competition and for the benefit of consumers. \nConsistent with the authority of the Commission, such rules may include \ninterpretive rules and general statements of policy with respect to the \npractices prohibited under section 2.\n\nSEC. 4. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD UNDER THE FFDCA.\n\n    Section 505(j)(5)(D)(i) of the Federal Food, Drug, and Cosmetic Act \n(21 U.S.C. 355(j)(5)(D)(i)) is amended--\n            (1) in subclause (I)(bb)--\n                    (A) by redesignating subitem (CC) as subitem (EE); \n                and\n                    (B) by inserting after subitem (BB) the following:\n\n                                                    ``(CC) In a \n                                                declaratory judgment \n                                                action described in \n                                                subitem (AA), a court \n                                                dismisses the action \n                                                for lack of subject \n                                                matter jurisdiction, \n                                                either with or without \n                                                prejudice.\n\n                                                    ``(DD) The \n                                                applicant files with \n                                                the Secretary a \n                                                covenant by the patent \n                                                owner that the patent \n                                                owner will not sue the \n                                                applicant for \n                                                infringement with \n                                                respect to the \n                                                patent.''; and\n\n            (2) in subclause (V), by inserting ``section 2 of the \n        Protecting Consumer Access to Generic Drugs Act of 2007 or'' \n        after ``that the agreement has violated''.\n\nSEC. 5. NOTICE AND CERTIFICATION OF AGREEMENTS.\n\n    (a) Notice of All Agreements.--Section 1112(c)(2) of the Medicare \nPrescription Drug, Improvement, and Modernization Act of 2003 (21 \nU.S.C. 3155 note) is amended by--\n            (1) striking ``the Commission the'' and inserting ``the \n        Commission (1) the''; and\n            (2) inserting before the period at the end the following: \n        ``; and (2) a description of the subject matter of any other \n        agreement the parties enter into within 30 days of an entering \n        into an agreement covered by subsection (a) or (b)''.\n    (b) Certification of Agreements.--Section 1112 of such Act is \namended by adding at the end the following:\n    ``(d) Certification.--The Chief Executive Officer or the company \nofficial responsible for negotiating any agreement required to be filed \nunder subsection (a), (b), or (c) shall execute and file with the \nAssistant Attorney General and the Commission a certification as \nfollows: `I declare under penalty of perjury that the following is true \nand correct: The materials filed with the Federal Trade Commission and \nthe Department of Justice under section 1112 of subtitle B of title XI \nof the Medicare Prescription Drug, Improvement, and Modernization Act \nof 2003, with respect to the agreement referenced in this \ncertification: (1) represent the complete, final, and exclusive \nagreement between the parties; (2) include any ancillary agreements \nthat are contingent upon, provide a contingent condition for, or are \notherwise related to, the referenced agreement; and (3) include written \ndescriptions of any oral agreements, representations, commitments, or \npromises between the parties that are responsive to subsection (a) or \n(b) of such section 1112 and have not been reduced to writing.'.''."
}